



Ashish V Khemka

Chairman & MD
AMN Life Science Pvt Ltd.



This results in shorter timelines, fewer repeat experiments and more consistent, accurate submissions, reviewed by qualified scientists under strict data integrity, GxP and information-security controls.

What has helped AMN Life Science scale its formulation and API capabilities across regulated and emerging markets?

Access to Life... Access to Healthy Life is more than a line, it is the promise we scale by one quality standard, for regulated or emerging markets. Global market and client access footprint has enabled AMN to build its strong formulation and API capabilities across diverse geographies.

Our R&D center covers formulation and analytical development, lab-scale trials and technology transfer, with formats including orally disintegrating tablets, sustained-release capsules and taste-masked syrups, designed to remain stable across various climatic zones.

Manufacturing runs across two sites, a general-portfolio facility at Kala-Amb, Chandigarh, and a beta-lactam unit at Bhilad, Vapi, WHO cGMP and EU GMP compliant, with approvals from Health Canada, TGA, UAE, UK MHRA and SAHPRA.

Over 300 registered products anchor our branded generics business across Africa and South-East Asia,

while EU dossier supports our Malta and London offices. Our API plant at Chennai which supports in-house manufacturing alongside R&D gives us control over quality from API to finished dosage form.

Which products and international markets will shape AMN Life Science's growth over the next five years?

Our vision is seamless supply of quality medicines worldwide, and our mission is to become an integrated pharmaceutical company delivering them affordably. Four themes will drive growth: *"differentiated products, regulated-market expansion, selected emerging markets and stronger partnerships."*

We offer a therapeutic portfolio built to treat, not just manage, spanning chronic and acute care. We are bringing sachet manufacturing into our portfolio, starting with "Metformin sachets" for UK compliance, giving patients an easier alternative to tablets and capsules.

In regulated and SRA markets, our EU GMP, Health Canada, TGA and UK MHRA approvals underpin a growing dossier pipeline of in-licensed products. While Africa, South-East Asia and MENA remain key emerging markets. Partnerships, including injectables, cephalosporins, and oncology segment will keep adding products, in service of our promise: *Access to Healthy Life!* ■

How is AMN Life Science using AI and data to improve pharmaceutical research, manufacturing, and quality control?

At AMN Life Science, AI and data are enablers of speed, quality and smarter decision-making. In R&D, AI can accelerate literature and patent intelligence, support in defining Quality Target Product Profile (QTPP) and Critical Quality Attribute (CQA), risk assessment, experimental design. In analytical development, it can strengthen Analytical QbD, method development, forced-degradation studies, impurity profiling and method validation aligned with ICH Q14 and Q2(R2).

For regulatory filings, AI supports dossier gap assessment, checklist verification and deficiency-response review, enables a first-time-right approach: Right Data -> Right Document -> Right Justification -> Right Market -> First-Time-Right Filing.